Recombinant AMACR / p504S Antibody (Prostate Cancer Marker), Clone: [rAMACR/6369], Mouse, Monoclonal

Artikelnummer: NSJ-V9306SAF-100UG
Artikelname: Recombinant AMACR / p504S Antibody (Prostate Cancer Marker), Clone: [rAMACR/6369], Mouse, Monoclonal
Artikelnummer: NSJ-V9306SAF-100UG
Hersteller Artikelnummer: V9306SAF-100UG
Alternativnummer: NSJ-V9306SAF-100UG
Hersteller: NSJ Bioreagents
Wirt: Mouse
Kategorie: Antikörper
Applikation: IHC-P, WB
Spezies Reaktivität: Human
Immunogen: Recombinant full-length human AMACR protein was used as the immunogen for the recombinant AMACR antibody.
This antibody recognizes a protein of 42kDa, which is identified as AMACR, also known as p504S. It is an enzyme that is involved in bile acid biosynthesis and -oxidation of branched-chain fatty acids. AMACR is essential in lipid metabolism. It is expressed in cells of premalignant high-grade prostatic intraepithelial neoplasia (HGPIN) and prostate adenocarcinoma. The majority of the carcinoma cells show a distinct granular cytoplasmic staining reaction. AMACR is present at low or undetectable levels in glandular epithelial cells of normal prostate and benign prostatic hyperplasia. A spotty granular cytoplasmic staining is seen in a few cells of the benign glands. AMACR is expressed in normal liver (hepatocytes), kidney (tubular epithelial cells) and gall bladder (epithelial cells). Expression has also been found in lung (bronchial epithelial cells) and colon (colonic surface epithelium). AMACR expression can also be found in hepatocellular carcinoma and kidney carcinoma. Past studies have also shown that AMACR is expressed in various colon carcinomas (well, moderately and poorly differentiated) and over expressed in prostate carcinoma.
Klonalität: Monoclonal
Klon-Bezeichnung: [rAMACR/6369]
UniProt: Q9UHK6
Reinheit: Protein A/G affinity
Formulierung: 1 mg/ml in 1X PBS, BSA free, sodium azide free
Antibody Type: Primary Antibody
Application Verdünnung: Western blot: 1-2ug/ml,Immunohistochemistry (FFPE): 1-2ug/ml
Anwendungsbeschreibung: Optimal dilution of the recombinant AMACR antibody should be determined by the researcher.